The Discord Effortpost Defense

Man drops a 4,000-word protocol breakdown with 17 citations and a tapering schedule, then closes with 'but obviously not medical advice.'

Filed under Survodutide ·Tesofensine ·Tirzepatide · #cope ·#stack-life ·#discord

Active Compounds

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Tesofensine · Monoamine Reuptake Inhibitor

A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) that produced up to 10.6% weight loss in Phase 2 trials — roughly double the efficacy of older appetite suppressants. Approved in Mexico; not yet FDA-approved.

Tirzepatide · Dual GIP/GLP-1 Receptor Agonist

A dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.

RX: Survodutide · Tesofensine · Tirzepatide
Dosage: 4,000 words PO
Half-life: until the thread locks
Source: manual
Tags: cope , stack-life , discord
Stamped: 2026-06-15 · Cycle 024
Lot #: LOT-20260615T12:07:47.239Z